Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
At one point, my investment in RXMD alone was worth $5M. LMAO. I'm still here posting today. Well, I do think this year will be truly different.
2023 will see a lot of new millionaires
By Q4 RXMD will be in the $20s and hopefully, NXPL will also.
July 1 is an interesting day based on the CFO's employment agreement.
"Extremely complicated agreement with TMall and Alibaba, which requires a lot of joint ventures and different things, so for that reason, we expect over the next 60-90 days, we will be putting out a lot of news related to that and related to those potential joint ventures. So the appropriate time it is my intention that the company will become substantially more active and provide information to shareholders as to its current activities and or future plans. I look forward to a great and prosperous new year." - May 31, 2023, Charles Fernandez, CEO
In 60 days, Progressive Care will release the Q2 10Q, which is highly expected to show the company will become profitable. M/A news in healthcare are highly expected to be announced by NextPlat by the end of July when the current Alibaba agreement is set to be renewed.
"It doesn’t take rocket science to get an idea of what’s happening here. A recognized “restructuring whiz” with more than 100 significant mergers, acquisitions and product-development projects under his belt has made a substantial investment in and taken charge of RXMD. If the past is any prologue to the future, and if Fernandez’s record of success is any indication of future performance, he’s about to apply his “wizardry” to help supercharge growth at Progressive Care."
Ill be under the covers sucking my thumb and wondering where it all went wrong
Baaaaaahahahaha!! Priceless, my friend.
You had me at mesh basket Turbo =)
Thank you for the comic relief, I needed a good belly laugh tonight. LOL G'nite Sir.
It sounds just like a harley
I ride three wheel bikes with a mesh basket for my cane
.....May just have to settle for some baseball cards in the wheel spokes of a reclaimed banana seat Schwinn StingRay =)
The two year silent period with Jay running the show during the potential uplisting process, followed by another 7 months of silence from Fernandez is far beyond the patience of many IMO. Waiting 3 years with minimal returns on your investment seems like a close second to taking up knitting. LOL
Especially with the market screaming bullish during the current earnings report season.
How long is long enough? Cuz the weather is great and I don’t think RXMD bought you that new motorcycle yet? ;)
If people don't have the guts to wait, maybe they should go take up a hobby like knitting.
Oh I got your point, don’t worry.
Completely missed the point, along with a few others. Enron and RXMD couldn't be more different. Read again, the response and correlation I was making while speaking with Turbo was in regards to how "taking comfort" in following the money doesn't always work. The silence from Fernandez is unprecedented, nobody can deny that. The current PPS and lack of volume is the sole responsibility of Fernandez for not being communicative with shareholders. Nothing for anyone to get excited about when the future is an enigma wrapped in a mystery.
Consider RXMD a lottery ticket until further notice, companies that shuffle CEOs, fail to provide reasonable forward looking statements and unrealistic plans for the future are not what investors are seeking in this bull market environment. The grossly over inflated market cap of $5 Billion in 5 years, as Jay communicated, is a pipe dream. No way that'll be remotely possible in 5 years for a company making $40M/year. It's a very long road from $40M/year to $1B a year to obtain that valuation
FOCUS on the facts Daniel-San... reading is fundamental =)
And now here comes the hail mary Enron comparisons. Too funny.
Knocked a few hundred off of the ask at 3.8, it immediately jumped up to 4.5. SMH
I’m assuming he’s meaning pre-split. Your response about market cap is still valid though
I'm right here with you.
Impatiently waiting here Gedi.
That is true Captain. Thankfully i am not sweating here anymore. I think if you connect the dots you will see the picture. Good luck to you my friend.
They have told you that many times. Go back and read the pr's and fillings.
Obviously not, however selective reading may cause that. I provided multiple examples of where following the money wasn't a wise bet. The point being made here is that following the money is never an assurance towards future wealth.
CEOs get ahead of their skis all the time, now we can add Chucky Fernandez to the list. He invested millions with nothing to show for it, imagine how much interest he's now losing on that $7M at today's APY savings and Bond yields.
#notMyCEO
OMG… you can’t seriously be comparing Theranos to RXMD. LOL LOL LOL
Certainly is.... Ask billionaire Larry Ellison from Oracle amongst others who got fleeced by Elizabeth Holmes at Theranos, for one.
Same apploes applies to FTX and Sam Bankman. Valid DD is up to each individual investor to perform. Blindly following the money is a fools game.
The point IS, following the money is never a sure thing as I was elaborating to Turbo. Companies may be different, but the methodology of putting your money where the rich folks do, doesn't always work out for the best.
Lastly, hard not to notice ZERO shares traded today. Must just be another slow week due to the "holiday"?
Way different...but nice try.
Not neccesarily always true my friend Turbo...
Enron, Theranos, Perdue and Madoff are just a few examples of where "following the money" didn't work out well for anyone.
Let's all take a deep breath. Who puts millions of dollars in a company then runs it into the ground and loses themselves millions? That makes almost zero sense.
Relax and see the bigger picture. Follow the flow of the rich peoples money, if yours is in the same place you should be alright.
Makes Total "SENSE" for a company Trading below 2 cents .... LOL Old price!!
Below $2.00 soon enough...
Dont forget his LONG successful history CEO should know what he is doing can affect pps up or down, the point is why he chooses to cause it down.
If that's the theory on what's happening here, I have some "ocean front" property up for sale in Wyoming.
Last week the lack of interest/volume was attributed to suspicions of an extended Memorial Day. What holiday is it this week.... have potential investors hit the roads already for Fathers Day?
Pfff.... dead money walking here, Fernandez for the "L"
OK, at $0.01 the marketcap would be $52,000. That makes total sense for a company with over $40M annual revenue and $7M Cash on hand. LOL!
$RXMD
Then they should tell us that. They have chosen to keep their shareholders in the dark. They deserve to be called out for their lack of leadership.
You have to be insane to really believe that, I personally believe Fernandez and Company are working on a plan that both RXMD and NXPL will be the new standard for health care. And by Q4 we will all see.
Well at this point neither of us is right or wrong as they don’t update the shareholders.
That makes absolutely zero sense
IMO it’s all intentional. He wants the SP to tank to presplit subpenny.
BINGO, my friend. The dangling carrot from Fernandez & Friends in the hopes of a miracle here are perplexing.
Shareholders of RXMD are not making money during one of the best bull markets we have seen. I admire the conviction of those putting their faith in such a lack luster CEO, however the time will come when some had enough of this CEO and throw in the proverbial towel.
Seven months without any communication from new CEO is pitiful, he missed a tremendous opportunity to introduce himself during annual shareholder conference call, which he actively chose to deny shareholders of. Every CEO prior towed the line, even Sleepy Jay (despite the painful monotone voice) held the quarterly and annual calls on time as investors expected.
Major opportunity was lost by Fernandez, time to step down and let someone else grow the business. Clearly this guy does not possess the necessary pharma business acumen; nor is he the leader RXMD needed for uplisting to NASDAQ. He's doing nothing to keep investors interested, absolutely nothing beside throw money onto RXMDs balance sheet.
Zero interest is the real one. Nobody wants to invest in something after a billion share rs
A weak CEO, lacking basic communication skills leads to weak volume, for one.
Not to mention the sneaky RS he pulled on shareholders, that certainly doesn't boost confidence nor volume.
No news or updates. For one.
Why is there weak volume?
Conspiracy theories too??
That’s not accurate. Share price is here around the $4.00 range because of the weak volume. No one is purposely tanking the share price. If they wanted to tank it it would be much lower
Followers
|
744
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
194941
|
Created
|
01/09/11
|
Type
|
Free
|
Moderators gedi8 Truth022809 stockforce TrackDude MrMike241 |
Progressive Care Gains SEC Reporting Status
See on website
Miami, FL – April 12, 2022 – Globe Newswire via NewMediaWire – Progressive Care, Inc. (OTCQB: RXMD) (the “Company”), a personalized healthcare services and technology provider, today announced that, effective April 11, 2022, its Registration Statement on Form 10 filed with the U.S. Securities and Exchange (the “SEC”) to register its shares of common stock under Section 12(g) of the Securities Exchange Act of 1934 (the “Exchange Act”) became automatically effective.
The effective Form 10 obligates the Company to file Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, in addition to complying with all other obligations under the Exchange Act. In addition, management and certain shareholders are subject to the beneficial ownership reporting requirements of Section 13 and 16 of the Exchange Act.
Alan Jay Weisberg, Chairman and Chief Executive Officer of the Company said, “For me, it was always important to have the Company become fully reporting with the SEC. I know how critical it is for individual and institutional investors to have the Company file its financial reports with the SEC as it provides a higher level of confidence in the information reported by the Company and a superior level of transparency. I believe that the Company’s compliance with the Exchange Act will ultimately help drive shareholder value and enable us to access higher quality institutional capital. We remain committed to strong corporate governance and steadfast in pursuit of our journey to Nasdaq.”
To view the Form 10 filling, please click:
https://www.sec.gov/Archives/edgar/data/0001402945/000149315222009357/form10-12ga.htm
Key Financial Highlights for Year Ended December 31, 2021
• Revenue at $38.9 million
- COVID-19 testing revenue of approximately $4.3 million
- ClearMetrX TPA and pharmacy dispensing revenue related to 340B earned $2.8 million on total billings of $19 million
• Gross margin increased to 26% in 2021, from 23% in 2020
• EBITDA increased to $167,000 in 2021 from $7,000 in 2020
• Cash balance of $1.4 million as of December 31, 2021
Business Highlights for the Year Ended December 31, 2021
• Re-implemented upgraded pharmacy software system
• Expanded COVID-19 business into corporate-focused services and institutional clients
• Strengthened reputation in the 340B sector by adding eight new contracts
• Filed initial S-1 registration statement
• Submitted application for uplisting to Nasdaq
Q4 2021 Reflected a Positive Bounce Back in Business
• Increase of 10% in prescription revenue to $8.9 million in the fourth quarter of 2021, from $8.1 million in the third quarter of 2021
• Increase of 8% in prescriptions filled to 114,000 in the fourth quarter of 2021, from 106,000 in the third quarter of 2021
PRODUCTS AND SERVICES
Advances in HIV/AIDS treatment has greatly increased the ability of those suffering from the disease to manage their symptoms and live longer, healthier lives. Effective management of the disease begins with taking the right medications with the right dose at the right times. For those in the HIV/AIDS community, adhering to the very strict dietary and medicinal requirements can be extremely difficult. Normal activities are often interrupted and sometimes prevented by the struggle to be in compliance.
PharmCo wants to ease this burden on those impacted by this life altering disease. We aim to make compliance with prescription regiments as easy as possible. By understanding the sensitive nature of HIV/AIDS and the needs of those afflicted, PharmCo provides the following services to patients with these special needs:
1. Confidential packaging
2. Packaging tailored to suit a patient's individual life style
3. Free delivery from a variety of sources including PharmCo's proprietary delivery fleet
4. A staff that is well trained in acute illnesses, who understands the patient's needs and
concerns
5. 24 hour emergency support
6. Timely availability of specialty medications due to our extensive inventory
7. Access to newly developed medications
PharmCo is a fully accredited DME supplier. In November 2010, as part of Medicare's competitive bidding, PharmCo was awarded a three year contract to supply hospital beds, oxygen supplies, power wheelchairs, scooters, walkers, and other related equipment and accessories in South Florida. PharmCo carries an extensive inventory of equipment and accessories with most special requests being honored with same day or next day delivery. The company offers both sales and rentals with size, color, style, and brand options available on the majority of products. Most importantly, the staff is knowledgeable, helpful and dedicated to providing superior customer service.
PharmCo offers home service and maintenance, defective product replacements, and free home installation and instruction.
PharmCo's institutional clients have come to depend on the company's proven accuracy, dispensing methods, and immediate response time. With PharmCo compliance and efficiency assistance, long term care institutions are able to provide the highest level of continued care to their patients. PharmCo provides purchasing, repackaging and dispensing of both prescription and non-prescription pharmaceutical products. PharmCo utilizes a unit-of-dose packaging system as opposed to traditional vials used for its retail customers. This method of distribution improves control and patient compliance with recommended drug therapy by increasing the timeliness and accuracy of medication dispensing. PharmCo also provides computerized maintenance of patient prescription histories, third party billing and consultant pharmacist services. Its consulting services consist primarily of evaluation of monthly patient drug therapy and monitoring the institution’s drug distribution system.
Long term care institutions can count on PharmCo for the following services:
1. On time, same day deliveries available twice a day with 24 hour emergency support
2. Language assistance in English, Spanish, French, Creole, Portuguese, Russian, and Hebrew
3. Unit-dose packaging options tailored the facility's needs
4. Prescription data accuracy
5. Extensive medication and DME inventory
6. Access to OTC medications, nutritional products and personal hygiene items
7. Provision and review of medication carts
8. Monthly pharmacy consultations- drug interactions, redundant therapies, side effects, etc.
9. Compliance updates and consultations
10. Staff Training
11. Exceptional customer service.
Toll Free: 888-919-7411 Phone: 305-919-7399 Fax: 305-919-7424
HOURS
Monday- Thursday 8:30 AM - 6:30 PM
Friday 8:30 AM - 6:00 PM
Saturday 11:00 AM - 4:00 PM
PharmCo currently services: Miami-Dade, Broward, Palm Beach, Martin, and St. Lucie Counties.
Progressive Care Reports Full Year 2021 Financial Results Highlighted by $38.9 Million in RevenueGLOBENEWSWIRE – 11:16 AM ET 03/29/2022 |
Progressive Care’s PharmcoRx Gains Status as Approved COVID-19 Test Vendor in the U.S. for Travel to Beijing Winter Olympic Games in ChinaGLOBENEWSWIRE – 7:00 AM ET 02/02/2022
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |